SCHEMBL6858670

SCHEMBL6858670

CC1CN(c2cccc(C(C)NC(=O)C=Cc3cc(F)cc(F)c3)c2)CCO1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 2/20 0.61
CYP3A4 P08684 2/20 0.61
KCNQ3 O43525 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP19A1 P11511 1/20 0.61
CYP2C9 P11712 1/20 0.61
GPER1 Q99527 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ACACB O00763 2/20 0.40
LMNA P02545 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKG1 Q13976 1/20 0.38
PIK3CB P42338 4/20 0.37
PIK3CD O00329 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CG P48736 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6650988 0.94 KCNQ2 (0.62) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL30796249 0.94 KCNQ2 (0.62) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6681217 0.94 KCNQ2 (0.62) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6650990 0.94 KCNQ2 (0.62) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6858122 0.94 KCNQ2 (0.62) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6683606 0.93 KCNQ2 (0.64) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6858114 0.93 KCNQ2 (0.64) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6683610 0.93 KCNQ2 (0.64) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6683615 0.93 KCNQ2 (0.64) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1
SCHEMBL6858587 0.90 CYP3A4 (0.75) KCNQ2CYP3A4KCNQ3CYP1A2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831080-B2 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents BRISTOL-MYERS SQUIBB COMPANY 2004-12-14 US disclosed